Jose M. Trevejo - Mar 8, 2023 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Chief Medical Officer
Signature: s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol: TARS
Transactions as of: Mar 8, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/10/2023, 06:28 PM
Previous filing: Feb 3, 2022
Next filing: Mar 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Stock Option (right to buy)	Award	$0	+45.5K		$0.00	45.5K	Mar 8, 2023	Common Stock	45.5K	$15.00	Direct	F1
transaction	TARS	Restricted Stock Units	Award	$0	+30.8K		$0.00	30.8K	Mar 8, 2023	Common Stock	30.8K		Direct	F2, F3

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the option shares shall vest on March 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
F2	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3	25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026, and 2027, subject to the Reporting Person's continuous service.